Surrozen (NASDAQ:SRZN – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.
Insider and Institutional Ownership
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Surrozen and MediWound”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $3.48 million | 104.20 | -$242.03 million | ($33.37) | -0.95 |
| MediWound | $16.96 million | 13.43 | -$23.88 million | ($2.10) | -8.44 |
MediWound has higher revenue and earnings than Surrozen. MediWound is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Surrozen and MediWound, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 0 | 2 | 1 | 2.75 |
| MediWound | 1 | 1 | 3 | 0 | 2.40 |
Surrozen presently has a consensus target price of $38.00, indicating a potential upside of 20.41%. MediWound has a consensus target price of $31.67, indicating a potential upside of 78.71%. Given MediWound’s higher possible upside, analysts plainly believe MediWound is more favorable than Surrozen.
Profitability
This table compares Surrozen and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -7,476.67% | -4,055.04% | -118.00% |
| MediWound | -140.80% | -65.79% | -30.16% |
Risk and Volatility
Surrozen has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.
Summary
MediWound beats Surrozen on 8 of the 15 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
